Interferon alfa-2c

DB15131InvestigationalProtein Based Therapies

Interferon alfa-2c is under investigation in clinical trial NCT00485563 (A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma).

Mechanism: Pharmacologically active on Interferon alpha/beta receptor (IFNAR)
Curator reviewed
Also known as: Intron-A

Resolves to

Compound

UNIIVW75A46X0KCAS142192-09-4

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

195Drug interactionsStructured to mechanism, not free text

11Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which companies are running trials of Interferon alfa-2c, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account